Skip to content

    Ovarian Cancer Health Center

    Medical Reference Related to Ovarian Cancer

    1. Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent or Persistent Ovarian Epithelial Cancer

      Treatment of recurrent ovarian epithelial cancer may include the following:Chemotherapy using one or more anticancer drugs, with or without surgery.A clinical trial of surgery.A clinical trial of targeted therapy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent ovarian epithelial cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.

    2. Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Ovarian Low Malignant Potential Tumors

      A link to a list of current clinical trials is included for each treatment section. For some stages, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Early Stage Ovarian Low Malignant Potential Tumors (Stage I and II)Surgery is the standard treatment for early stage ovarian low malignant potential tumor. The type of surgery usually depends on whether a woman plans to have children.For women who plan to have children, surgery is either:unilateral salpingo-oophorectomy; orpartial oophorectomy.To prevent recurrence of disease, most doctors recommend surgery to remove the remaining ovarian tissue when a woman no longer plans to have children.For women who do not plan to have children, treatment may be hysterectomy and bilateral salpingo-oophorectomy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage I borderline ovarian surface epithelial-stromal

    3. Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062935-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Germ Cell Tumors Treatment

    4. Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage II Ovarian Germ Cell Tumors

      DysgerminomasStandard treatment options: Total abdominal hysterectomy and bilateral salpingo-oophorectomy with adjuvant radiation therapy or chemotherapy.Unilateral salpingo-oophorectomy with adjuvant chemotherapy.For patients with stage II dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy are usually performed. For the younger patient who wants to preserve fertility, a unilateral salpingo-oophorectomy may be considered standard therapy, depending on the age of the patient, and adjuvant chemotherapy should be given. (Refer to the PDQ summary on Sexuality and Reproductive Issues for more information on fertility.)These patients should receive adjuvant treatment. Options include radiation therapy or chemotherapy. A disadvantage of the former is loss of fertility resulting from ovarian failure. Experience with adjuvant chemotherapy is limited, but considering the effectiveness of chemotherapy in tumors other than dysgerminoma and its effectiveness in

    5. Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage Information for Ovarian Epithelial Cancer

      In the absence of extra-abdominal metastatic disease, definitive staging of ovarian cancer requires surgery. The role of surgery in patients with stage IV disease and extra-abdominal disease is yet to be established. If disease appears to be limited to the ovaries or pelvis, it is essential at laparotomy to examine and biopsy or to obtain cytologic brushings of the diaphragm, both paracolic gutters, the pelvic peritoneum, para-aortic and pelvic nodes, and infracolic omentum, and to obtain peritoneal washings.[1]The serum CA 125 level is valuable in the follow-up and restaging of patients who have elevated CA 125 levels at the time of diagnosis.[2,3,4] While an elevated CA 125 level indicates a high probability of epithelial ovarian cancer, a negative CA 125 level cannot be used to exclude the presence of residual disease.[5] CA 125 levels can also be elevated in other malignancies and benign gynecologic problems such as endometriosis, and CA 125 levels should be used with a

    6. Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (07 / 30 / 2014)

      The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.SignificanceUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

    7. Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Description of the Evidence

      BackgroundIncidence and mortalityOvarian cancer is the fifth leading cause of cancer death among women in the United States and has the highest mortality rate of all gynecologic cancers.[1] It is estimated that 22,240 new cases of ovarian cancer will be diagnosed in the United States in 2013, and 14,030 women will die of this disease.[1] The median age at diagnosis is 63 years.[2] The prognosis for survival from ovarian cancer largely depends on the extent of disease at diagnosis, which is usually advanced, with only about 15% of women presenting with localized disease at diagnosis.[1,2]From 2005 to 2009, incidence rates decreased by 0.9% per year, and mortality rates decreased by 2.0% per year.[1]Ovarian cancer is rare; the lifetime risk of being diagnosed with ovarian cancer is 1.38%.[2]Types of Ovarian CancerThe term ovarian cancer encompasses a heterogeneous group of malignant tumors of ovarian origin that may arise from germ cells, stromal tissue, or

    8. Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary

      About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

    9. Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary

      Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of ovarian low-malignant potential tumors. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a

    10. Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Ovarian Germ Cell Tumors

      Ovarian germ cell tumor is a disease in which malignant (cancer) cells form in the germ (egg) cells of the ovary. Germ cell tumors begin in the reproductive cells (egg or sperm) of the body. Ovarian germ cell tumors usually occur in teenage girls or young women and most often affect just one ovary. The ovaries are a pair of organs in the female reproductive system. They are located in the ...

    Displaying 21 - 30 of 127 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

    Today on WebMD

    Ovarian cancer illustration
    What are the symptoms?
    doctory with x-ray
    Get to know the Symptoms.
     
    cancer cell
    HPV is the top cause. Find out more.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Integrative Medicine Cancer Quiz
    QUIZ
    Lifestyle Tips for Depression Slideshow
    SLIDESHOW
     
    Screening Tests for Women
    Slideshow
    Graphic of ovaries within reproductive system
    VIDEO
     
    Ovarian Cancer Marker
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Healthy meal with salmon
    Article